WALTHAM, Mass.--(BUSINESS WIRE)--June 21, 2006--Adnexus Therapeutics(TM), Inc. (formerly Compound Therapeutics, Inc.) announced today that its anti-angiogenesis product candidate, Angiocept(TM) (CT-322), has cleared review by the U.S. Food and Drug Administration (FDA) following Adnexus' filing of an Investigational New Drug (IND) application. Adnexus is in the process of initiating a Phase 1 trial of CT-322 in patients with cancer.
